<DOC>
	<DOCNO>NCT01316952</DOCNO>
	<brief_summary>A cluster report hypersensitivity reaction among patient switch carvedilol ( immediate release formulation , refer hereafter carvedilol ) carvedilol extend release receive initial post-launch period carvedilol extend release . In follow observation , product label agent update nested case control study subsequently conduct examine risk serious hypersensitivity reaction i.e . anaphylactic reaction and/or angioedema among patient use carvedilol extend release compare carvedilol separately compare long act beta ( β ) -blockers . This propose analysis update previously conduct analysis use database , LabRx , contain 2 additional year data , provide large number carvedilol extend release exposed subject .</brief_summary>
	<brief_title>Coreg HSRs-Updated Analysis</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Adrenergic Antagonists</mesh_term>
	<criteria>At least one prescription claim βblocker followup time available database . At least one month enrollment healthcare plan</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>carvedilol</keyword>
	<keyword>propranolol</keyword>
	<keyword>hypersensitivity reaction</keyword>
	<keyword>beta- blocker</keyword>
	<keyword>Coreg</keyword>
</DOC>